Loading...
•
Mar 31, 2022
Mersana Q1 2022 Earnings Report
Mersana reported financial results and provided a business update for the first quarter ended March 31, 2022.
Key Takeaways
Mersana Therapeutics reported its Q1 2022 financial results and provided a business update, highlighting the potential of UpRi to transform ovarian cancer treatment and the advancement of XMT-1660 and XMT-2056 into clinical trials.
UpRi has the potential to transform the treatment paradigm for patients with ovarian cancer.
Mersana's development strategy is designed to advance UpRi from platinum-resistant ovarian cancer into earlier lines of treatment.
Mersana has a strengthened balance sheet and preparations to move XMT-1660 and XMT-2056 into the clinic in the near term.
Mersana anticipates delivering clinical data across all three of its platforms and building a leading ADC company.